CLINICAL RESEARCH: CLINICAL TRIAL
Randomized Comparison of Percutaneous Coronary Intervention With Coronary Artery Bypass Grafting in Diabetic Patients1-Year Results of the CARDia (Coronary Artery Revascularization in Diabetes) Trial
Akhil Kapur, MBChB, MD*,
Roger J. Hall, MD , ,
Iqbal S. Malik, MMBChir, PhD,
Ayesha C. Qureshi, MBBS*,
Jeremy Butts, MBBS,
Mark de Belder, MD ,
Andreas Baumbach, MS||,
Gianni Angelini, MD, MCh||,
Adam de Belder, MBBS, MD¶,
Keith G. Oldroyd, MBChB, MD#,
Marcus Flather, MBBS,**,
Michael Roughton, MSc**,
Petros Nihoyannopoulos, MD,
Jens Peder Bagger, MBBS, DSc,
Kenneth Morgan, MBChB, BSc and
Kevin J. Beatt, MBBS, PhD,*
* London Chest Hospital, Barts and The London NHS Trust, London, England
Imperial College Healthcare NHS Trust, London, England
Norfolk and Norwich University Hospitals, Norwich, England
James Cook University Hospital, Middlesbrough, England
|| Bristol Heart Institute, Bristol, England
¶ Royal Sussex County Hospital, Brighton, England
# Western Infirmary, Glasgow, Scotland
** Royal Brompton and Harefield NHS Foundation Trust, London, England
Mayday University Hospital, London, England
Manuscript received June 15, 2009;
revised manuscript received October 19, 2009,
accepted October 19, 2009.
* Reprint requests and correspondence: Dr. Kevin J. Beatt, Mayday University Hospital, London Road, London CR7 7YE, England (Email: dr.beatt{at}heartbeatt.com).
Objectives: The purpose of this study was to compare the safety and efficacy of percutaneous coronary intervention (PCI) with stenting against coronary artery bypass grafting (CABG) in patients with diabetes and symptomatic multivessel coronary artery disease.
Background: CABG is the established method of revascularization in patients with diabetes and multivessel coronary disease, but with advances in PCI, there is uncertainty whether CABG remains the preferred method of revascularization.
Methods: The primary outcome was a composite of all-cause mortality, myocardial infarction (MI), and stroke, and the main secondary outcome included the addition of repeat revascularization to the primary outcome events. A total of 510 diabetic patients with multivessel or complex single-vessel coronary disease from 24 centers were randomized to PCI plus stenting (and routine abciximab) or CABG. The primary comparison used a noninferiority method with the upper boundary of the 95% confidence interval (CI) not to exceed 1.3 to declare PCI noninferior. Bare-metal stents were used initially, but a switch to Cypher (sirolimus drug-eluting) stents (Cordis, Johnson & Johnson, Bridgewater, New Jersey) was made when these became available.
Results: At 1 year of follow-up, the composite rate of death, MI, and stroke was 10.5% in the CABG group and 13.0% in the PCI group (hazard ratio [HR]: 1.25, 95% CI: 0.75 to 2.09; p = 0.39), all-cause mortality rates were 3.2% and 3.2%, and the rates of death, MI, stroke, or repeat revascularization were 11.3% and 19.3% (HR: 1.77, 95% CI: 1.11 to 2.82; p = 0.02), respectively. When the patients who underwent CABG were compared with the subset of patients who received drug-eluting stents (69% of patients), the primary outcome rates were 12.4% and 11.6% (HR: 0.93, 95% CI: 0.51 to 1.71; p = 0.82), respectively.
Conclusions: The CARDia (Coronary Artery Revascularization in Diabetes) trial is the first randomized trial of coronary revascularization in diabetic patients, but the 1-year results did not show that PCI is noninferior to CABG. However, the CARDia trial did show that multivessel PCI is feasible in patients with diabetes, but longer-term follow-up and data from other trials will be needed to provide a more precise comparison of the efficacy of these 2 revascularization strategies. (The Coronary Artery Revascularisation in Diabetes trial; ISRCTN19872154)
Key Words: coronary revascularization • diabetes • multivesssel disease
|
Abbreviations and Acronyms
| | BMS = bare-metal stent(s) | | CABG = coronary artery bypass grafting | | CI = confidence interval | | DES = drug-eluting stent(s) | | HR = hazard ratio | | MACCE = major adverse coronary and cerebral events | | MI = myocardial infarction | | PCI = percutaneous coronary intervention |
|
Related Article
-
Inside This Issue
J. Am. Coll. Cardiol. 2010 55: A32.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
R. A. Henderson, N. O'Flynn, and on behalf of the Guideline Development Group
Management of stable angina: summary of NICE guidance
Heart,
January 23, 2012;
(2012)
heartjnl-2011-301436v1.
[Full Text]
|
|
|
|
|
|
|
G. N. Levine, E. R. Bates, J. C. Blankenship, S. R. Bailey, J. A. Bittl, B. Cercek, C. E. Chambers, S. G. Ellis, R. A. Guyton, S. M. Hollenberg, et al.
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions
J. Am. Coll. Cardiol.,
December 6, 2011;
58(24):
e44 - e122.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. D. Hillis, P. K. Smith, J. L. Anderson, J. A. Bittl, C. R. Bridges, J. G. Byrne, J. E. Cigarroa, V. J. DiSesa, L. F. Hiratzka, A. M. Hutter Jr, et al.
2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the American Association for Thoracic Surgery, Society of Cardiovascular Anesthesiologists, and Society of Thoracic Surgeons
J. Am. Coll. Cardiol.,
December 6, 2011;
58(24):
e123 - e210.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Writing Committee Members, G. N. Levine, E. R. Bates, J. C. Blankenship, S. R. Bailey, J. A. Bittl, B. Cercek, C. E. Chambers, S. G. Ellis, R. A. Guyton, et al.
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions
Circulation,
December 6, 2011;
124(23):
e574 - e651.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Writing Committee Members, L. D. Hillis, P. K. Smith, J. L. Anderson, J. A. Bittl, C. R. Bridges, J. G. Byrne, J. E. Cigarroa, V. J. DiSesa, L. F. Hiratzka, et al.
2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
Circulation,
December 6, 2011;
124(23):
e652 - e735.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Kapur, A. C. Qureshi, S. Gallagher, M. Finlay, I. S. Malik, J. Mayet, M. Roughton, K. J. Beatt, R. J. Hall, and P. Nihoyannopoulos
Myocardial function may improve equally in diabetic patients following both multivessel percutaneous coronary intervention and coronary artery bypass grafting: results from a CARDia trial substudy
Eur Heart J Cardiovasc Imaging,
December 1, 2011;
12(12):
904 - 909.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Bebb and S. Wheatcroft
Chapter 7 Coronary revascularization in the patient with diabetes
Heart Disease and Diabetes,
December 1, 2011;
2(1):
med-9780199604562-chapter - med-9780199604562-chapter.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
M. Roffi, D. J. Angiolillo, and A. P. Kappetein
Current concepts on coronary revascularization in diabetic patients
Eur. Heart J.,
November 2, 2011;
32(22):
2748 - 2757.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Henderson and A. D. Timmis
Almanac 2011: stable coronary artery disease. An editorial overview of selected research that has driven recent advances in clinical cardiology
Heart,
October 1, 2011;
97(19):
1552 - 1559.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. P. Kappetein, T. E. Feldman, M. J. Mack, M.-C. Morice, D. R. Holmes, E. Stahle, K. D. Dawkins, F. W. Mohr, P. W. Serruys, and A. Colombo
Comparison of coronary bypass surgery with drug-eluting stenting for the treatment of left main and/or three-vessel disease: 3-year follow-up of the SYNTAX trial
Eur. Heart J.,
September 1, 2011;
32(17):
2125 - 2134.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Katsiki, V. G. Athyros, and D. P. Mikhailidis
Does Metabolic Syndrome Influence Outcome Following Percutaneous Coronary Intervention?
Angiology,
August 1, 2011;
62(6):
437 - 439.
[PDF]
|
|
|
|
|
|
|
H. Takagi, H. Manabe, and T. Umemoto
The Gordian knot of revascularization for multivessel coronary artery disease.
J. Thorac. Cardiovasc. Surg.,
July 1, 2011;
142(1):
241 - 242.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. R. Dixon and C. L. Grines
The Year in Interventional Cardiology
J. Am. Coll. Cardiol.,
May 31, 2011;
57(22):
2207 - 2220.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Onuma, J. J. Wykrzykowska, S. Garg, P. Vranckx, P. W. Serruys, and ARTS I and II Investigators
5-Year Follow-Up of Coronary Revascularization in Diabetic Patients With Multivessel Coronary Artery Disease: Insights From ARTS (Arterial Revascularization Therapy Study)-II and ARTS-I Trials
J. Am. Coll. Cardiol. Intv.,
March 1, 2011;
4(3):
317 - 323.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K.-H. Mak
The Continuing Diabetic Drug-Eluting Stents Saga: From Very-Late Stent Thrombosis to Very-Late Late Loss
J. Am. Coll. Cardiol. Intv.,
March 1, 2011;
4(3):
324 - 326.
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Cheng, L. Shi, S. Nie, F. Wang, X. Li, C. Xu, P. Wang, B. Yang, Q. Li, Z. Pan, et al.
The Same Chromosome 9p21.3 Locus Is Associated With Type 2 Diabetes and Coronary Artery Disease in a Chinese Han Population
Diabetes,
February 1, 2011;
60(2):
680 - 684.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D.-W. Park, Y.-H. Kim, H.-G. Song, J.-M. Ahn, J. Oh, W.-J. Kim, J.-Y. Lee, S.-J. Kang, S.-W. Lee, C.-W. Lee, et al.
Long-Term Comparison of Drug-Eluting Stents and Coronary Artery Bypass Grafting for Multivessel Coronary Revascularization: 5-Year Outcomes From the Asan Medical Center-Multivessel Revascularization Registry
J. Am. Coll. Cardiol.,
January 11, 2011;
57(2):
128 - 137.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Malik
Is coronary artery bypass grafting the treatment of choice for diabetic patients with multivessel disease? No
BMJ,
December 13, 2010;
341(dec13_1):
c6975 - c6975.
[Full Text]
|
|
|
|
|
|
|
Developed with the special contribution of the Eur, Authors/Task Force Members, W. Wijns, P. Kolh, N. Danchin, C. Di Mario, V. Falk, T. Folliguet, S. Garg, K. Huber, et al.
Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)
Eur. Heart J.,
October 2, 2010;
31(20):
2501 - 2555.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. K. Rutter and R. W. Nesto
Coronary revascularisation in the patient with diabetes: balancing risk and benefit
Heart,
September 1, 2010;
96(18):
1436 - 1440.
[Full Text]
[PDF]
|
|
|
|
|
|
|
The Task Force on Myocardial Revascularization of
Guidelines on myocardial revascularization
Eur J Cardiothorac Surg,
September 1, 2010;
38(Supplement_1):
S1 - S52.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Garg and P. W. Serruys
Coronary Stents: Current Status
J. Am. Coll. Cardiol.,
August 31, 2010;
56(10_Suppl_S):
S1 - S42.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Garg and P. W Serruys
Drug-eluting stents: a reappraisal
Heart,
April 1, 2010;
96(7):
489 - 493.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Garg, J. J. Wykrzykowska, and P. W. Serruys
Chapter 14 Stable coronary artery disease: medical therapy versus percutaneous coronary intervention versus surgery
Oxford Textbook of Interventional Cardiology,
January 1, 2010;
1(1):
med-9780199569083-chapter - med-9780199569083-chapter.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
A. Kapur and A. Qureshi
Chapter 21 Revascularization in diabetes mellitus
Oxford Textbook of Interventional Cardiology,
January 1, 2010;
1(1):
med-9780199569083-chapter - med-9780199569083-chapter.
[Abstract]
[Full Text]
|
|
|
|
